Evidence map›Paper›PMID 35967536›Full record

ArticleIndian journal of nephrology

Correlation of AKI with Risk Factors, Ventilatory Support, Renal Replacement Therapy in a Cohort of COVID-19 Patients.

Phanidhar Mogga, Shreevidya Venkatraman, Urjitha Rajagopalan, Prashanth Rajagopalan, Prabhu Radhan, Kumaresan Maithrayie, Sivaraj Padmanabhan, Swamikannu Murugan, Archana Nagarajan, Chandrasekaran Venkataraman and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Indian journal of nephrology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. [Severe post-COVID-19 dialysis dependence and inpatient acute kidney injury].Revista medica del Instituto Mexicano del Seguro Social · 2023
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Phanidhar MoggaDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Shreevidya VenkatramanDepartment of Internal Medicine, MGM Healthcare, Chennai, Tamil Nadu, India.
Urjitha RajagopalanDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Prashanth RajagopalanDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Prabhu RadhanDepartment of Radiology, MGM Healthcare, Chennai, Tamil Nadu, India.
Kumaresan MaithrayieDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Sivaraj PadmanabhanDepartment of Internal Medicine, MGM Healthcare, Chennai, Tamil Nadu, India.
Swamikannu MuruganDepartment of Internal Medicine, MGM Healthcare, Chennai, Tamil Nadu, India.
Archana NagarajanDepartment of Microbiology, MGM Healthcare, Chennai, Tamil Nadu, India.
Chandrasekaran VenkataramanDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Milly MathewDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Georgi AbrahamDepartment of Nephrology, MGM Healthcare, Chennai, Tamil Nadu, India.
Nancy LesleyDepartment of Statistical Analysis, MGM Healthcare, Chennai, Tamil Nadu, India.
Madras Medical Mission · INHealthcare Technology Innovation Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There is a scarcity of information on the incidence and outcomes of acute kidney injury (AKI) in COVID-19 patients in India. Therefore, we analyzed the correlation of AKI risk factors, ventilatory support, and renal replacement therapy and compared the outcomes of first and second COVID-19 waves in this tertiary care center. Methods: We retrospectively analyzed the patients' medical records with a positive RT-PCR for COVID-19 between July 2020 and May 2021. We looked at the clinical outcomes of the first and second COVID-19 waves and documented the frequency, risk factors for AKI, and the relationship between AKI and in-hospital mortality. Univariate and multivariate binomial logistic regression yielded odds ratios for the risk variables of AKI. Risk differences and age-adjusted odds ratios, as well as 99.5% confidence intervals, were used to compare COVID-19 outcomes between the first and second waves. Results: Of the 1260 hospitalized patients with COVID-19, 86 (6.8%) presented with AKI and 8 (0.7%) patients required dialysis. The most common comorbidity was diabetes mellitus (55.2%), hypertension (42.1%), hypothyroidism (11.3%), and coronary artery disease (8.1%). A total of 229 (18.17%) patients were admitted to ICU, 574 (45.5%) received ventilation, and 26 (2.0%) required mechanical ventilation.The incidence of in-hospital death in the patients with AKI as per the stage from 1 to 3 was 9 (15.8%), 7 (35%), and 5 (55.6%), respectively.Compared to the first wave, the second wave cohort had a lower risk of AKI (adj OR: 0.426; CI: 0.232-0.782) and mortality (adj OR: 0.252; CI: 0.090-0.707). Conclusions: In our study, AKI prevalence was 6.8%, the need for ventilation was 45.5%, ECMO 0.2%, and the mortality rate 2.9%. Second wave of COVID-19 exhibits improved clinical outcomes compared to the first wave.

Indexed as

Acute kidney injurycomorbiditiesCOVID-19

Identifiers

PMID35967536
PMCPMC9365008
OpenAlexW4285129638

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.